tradingkey.logo

Grail Inc

GRAL
查看详细走势图
91.090USD
+2.775+3.14%
收盘 12/19, 16:00美东报价延迟15分钟
3.29B总市值
亏损市盈率 TTM

Grail Inc

91.090
+2.775+3.14%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+3.14%

5天

+0.30%

1月

-2.63%

6月

+99.63%

今年开始到现在

+410.31%

1年

+396.40%

查看详细走势图

TradingKey Grail Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

Grail Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名93/404位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价105.00。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Grail Inc评分

相关信息

行业排名
93 / 404
全市场排名
209 / 4582
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 4 位分析师
买入
评级
105.000
目标均价
+5.21%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Grail Inc亮点

亮点风险
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
业绩高增长
公司营业收入稳步增长,连续3年增长126.09%
估值低估
公司最新PE估值-8.54,处于3年历史低位
机构减仓
最新机构持股24.89M股,环比减少19.54%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓,最新持仓市值1.71K

Grail Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Grail Inc简介

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
公司代码GRAL
公司Grail Inc
CEORagusa (Robert)
网址https://grail.com/

常见问题

Grail Inc(GRAL)的当前股价是多少?

Grail Inc(GRAL)的当前股价是 91.090。

Grail Inc的股票代码是什么?

Grail Inc的股票代码是GRAL。

Grail Inc股票的52周最高点是多少?

Grail Inc股票的52周最高点是115.760。

Grail Inc股票的52周最低点是多少?

Grail Inc股票的52周最低点是16.100。

Grail Inc的市值是多少?

Grail Inc的市值是3.29B。

Grail Inc的净利润是多少?

Grail Inc的净利润为-2.03B。

现在Grail Inc(GRAL)的股票是买入、持有还是卖出?

根据分析师评级,Grail Inc(GRAL)的总体评级为买入,目标价格为105.000。

Grail Inc(GRAL)股票的每股收益(EPS TTM)是多少

Grail Inc(GRAL)股票的每股收益(EPS TTM)是-10.662。
KeyAI